Furthermore, they disclosed that miR-181b can maintain atherosclerotic plaque and aneurysm stability by regulating TIMP metallopeptidase inhibitor 3 (TIMP-3) and elastin expression, which indicates that miR-181b is a key regulator in suppressing atherosclerosis and aneurysm progression and protecting plaque rupture, and it could be a potential therapeutic option for cardiovascular disease intervention in the future. The gene discussed is TIMP3; the disease is cardiovascular disorder.